Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2266 to 2280 of 7681 results

  1. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development [GID-TA11019] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Intrapartum Care - maternal hyponatremia

    In development [GID-NG10431] Expected publication date: TBC

    NICE guideline
    In development

  3. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development [GID-TA10994] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor ID 6476

    Awaiting development [GID-TA11584] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]

    In development [GID-TA11316] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

    In development [GID-TA11047] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Awaiting development [GID-TA11343] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]

    In development [GID-TA11570] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  9. MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's

    In development [GID-IPG10375] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  10. Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia

    In development [GID-IPG10268] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  11. MRI-guided focused ultrasound subthalamotomy for treating Parkinson's

    In development [GID-IPG10402] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  12. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development [GID-TA11096] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID6346

    In development [GID-TA11405] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Mexiletine hydrochloride for treating myotonia in children and adolescents with myotonic disorders [TS ID 11978]

      Status ...

    Technology appraisal guidance
    Topic selection

  15. Human immunoglobulin with recombinant human hyaluronidase for maintenance treatment of multifocal motor neuropathy in people of any age TSID 12033

      Status ...

    Technology appraisal guidance
    Topic selection